Switch theme
Sign up to access all valuation multiples
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
2011
14
LTM Revenue $5.0M
LTM EBITDA -$25.9M
$11.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CalciMedica has a last 12-month revenue of $5.0M and a last 12-month EBITDA of -$25.9M.
In the most recent fiscal year, CalciMedica achieved revenue of n/a and an EBITDA of -$34.2M.
CalciMedica expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CalciMedica valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$34.2M | -$25.2M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$35.8M | -$35.6M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, CalciMedica's stock price is $2.
CalciMedica has current market cap of $25.6M, and EV of $11.0M.
See CalciMedica trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.0M | $25.6M | XXX | XXX | XXX | XXX | $-1.34 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, CalciMedica has market cap of $25.6M and EV of $11.0M.
CalciMedica's trades at 2.2x LTM EV/Revenue multiple, and -0.4x LTM EBITDA.
Analysts estimate CalciMedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for CalciMedica and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $11.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.4x | XXX | XXX | XXX |
| P/E | -1.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCalciMedica's NTM/LTM revenue growth is 310%
CalciMedica's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.7M for the same period.
Over next 12 months, CalciMedica's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate CalciMedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for CalciMedica and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -26% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $2.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CalciMedica acquired XXX companies to date.
Last acquisition by CalciMedica was XXXXXXXX, XXXXX XXXXX XXXXXX . CalciMedica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was CalciMedica founded? | CalciMedica was founded in 2011. |
| Where is CalciMedica headquartered? | CalciMedica is headquartered in United States of America. |
| How many employees does CalciMedica have? | As of today, CalciMedica has 14 employees. |
| Who is the CEO of CalciMedica? | CalciMedica's CEO is Dr. A. Rachel Leheny, PhD. |
| Is CalciMedica publicy listed? | Yes, CalciMedica is a public company listed on NAS. |
| What is the stock symbol of CalciMedica? | CalciMedica trades under CALC ticker. |
| When did CalciMedica go public? | CalciMedica went public in 2020. |
| Who are competitors of CalciMedica? | Similar companies to CalciMedica include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of CalciMedica? | CalciMedica's current market cap is $25.6M |
| What is the current revenue of CalciMedica? | CalciMedica's last 12-month revenue is $5.0M. |
| What is the current EBITDA of CalciMedica? | CalciMedica's last 12-month EBITDA is -$25.9M. |
| What is the current EV/Revenue multiple of CalciMedica? | Current revenue multiple of CalciMedica is 2.2x. |
| What is the current EV/EBITDA multiple of CalciMedica? | Current EBITDA multiple of CalciMedica is -0.4x. |
| Is CalciMedica profitable? | Yes, CalciMedica is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
